Biotherapeutics in the era of biosimilars: what really matters is patient safety.
Declerck
Paul J
PJ
Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium. paul.declerck@pharm.kuleuven.be
D001688:Biological Products / Q000009:adverse effects / Q000493:pharmacokinetics / Q000592:standards; D001709:Biotechnology / Q000331:legislation & jurisprudence / Q000639:trends; D016568:Drugs, Generic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000592:standards; D006801:Humans; D007880:Legislation, Drug; D011358:Product Surveillance, Postmarketing; D017751:Safety Management; D009626:Terminology as Topic; D013810:Therapeutic Equivalency
D001688:Biological Products; D016568:Drugs, Generic